Evidence map›Paper›PMID 39859078›Full record

ReviewMedicina (Kaunas, Lithuania)2025

Mitochondrial Ribosomal Proteins and Cancer.

Huiyi Wu, Xiaowei Zhu, Huilin Zhou, Min Sha, Jun Ye, Hong Yu

Abstract readReview
In one paragraph

Review in Medicina (Kaunas, Lithuania), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. mCancer science · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. TSPAN4Frontiers in immunology · 2025
    Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Huiyi WuDepartment of Pathology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou 225300, China.ORCID 0009-0002-6694-9799
Xiaowei ZhuDepartment of Pathology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou 225300, China.
Huilin ZhouDepartment of Pathology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou 225300, China.
Min ShaTranslational Medicine Center, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou 225300, China.
Jun YeTranslational Medicine Center, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou 225300, China.
Hong YuDepartment of Pathology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou 225300, China.ORCID 0000-0001-5740-2543

Funding

the Project Foundation of Taizhou School of Clinical Medicine, Nanjing Medical University TZKY20220204 and TZKY20220205the Taizhou Social Development Project Foundation TS202309
6 · The paper itself

Abstract

Mitochondria play key roles in maintaining cell life and cell function, and their dysfunction can lead to cell damage. Mitochondrial ribosomal proteins (MRPs) are encoded by nuclear genes and are assembled within the mitochondria. MRPs are pivotal components of the mitochondrial ribosomes, which are responsible for translating 13 mitochondrial DNA-encoded proteins essential for the mitochondrial respiratory chain. Recent studies have underscored the importance of MRPs in cancer biology, revealing their altered expression patterns in various types of cancer and their potential as both prognostic biomarkers and therapeutic targets. Herein, we review the current knowledge regarding the multiple functions of MRPs in maintaining the structure of the mitochondrial ribosome and apoptosis, their implications for cancer susceptibility and progression, and the innovative strategies being developed to target MRPs and mitoribosome biogenesis in cancer therapy. This comprehensive overview aims to provide insights into the role of MRPs in cancer biology and highlight promising strategies for future precision oncology.

Indexed as

Mitochondrial ProteinsNeoplasmsRibosomal ProteinsHumansMitochondriaMitochondrial ProteinsRibosomal Proteinsapoptosisbiomarkermitochondrial dysfunctionmitoribosomeprecision oncology

Identifiers

PMID39859078
PMCPMC11766452

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.